Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Harvard Medical School signs macular degeneration agreement with Merck

May 30, 2006

Ganfort approved for glaucoma in E.U.

May 29, 2006

Chemokine CXCR4 antagonists reported by Merck & Co.

May 25, 2006

QR-435 to be studied for ocular herpes in animals

May 25, 2006

Hsp90 inhibitor shows activity in a murine model of choroidal neovascularization

May 18, 2006

Primate lentiviral vector promotes stable gene transfer in the retina in preclinical studies

May 17, 2006

Novel formulation of pegaptanib demonstrates sustained release in vivo

May 17, 2006

Merck & Co. prepares and tests novel calcium-activated potassium channel blockers for glaucoma

May 17, 2006

Snapshots on genetically engineered therapeutic strategies for choroidal neovascularization

May 16, 2006

SurModics grants Bausch & Lomb genistein license in retinal diseases

May 15, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...